Published in J Clin Invest on July 18, 2014
Host Biology in Light of the Microbiome: Ten Principles of Holobionts and Hologenomes. PLoS Biol (2015) 1.47
Antibiotics in early life and obesity. Nat Rev Endocrinol (2014) 1.25
The microbiome revolution. J Clin Invest (2014) 1.11
Fecal Microbiota Transplantation Eliminates Clostridium difficile in a Murine Model of Relapsing Disease. Infect Immun (2015) 0.93
Oral Administration of P. gingivalis Induces Dysbiosis of Gut Microbiota and Impaired Barrier Function Leading to Dissemination of Enterobacteria to the Liver. PLoS One (2015) 0.87
Development of the infant intestinal microbiome: A bird's eye view of a complex process. Birth Defects Res C Embryo Today (2015) 0.84
Novel riboswitch-binding flavin analog that protects mice against Clostridium difficile infection without inhibiting cecal flora. Antimicrob Agents Chemother (2015) 0.84
Clostridium difficile surface proteins are anchored to the cell wall using CWB2 motifs that recognise the anionic polymer PSII. Mol Microbiol (2015) 0.81
Regulation of Clostridium difficile Spore Formation by the SpoIIQ and SpoIIIA Proteins. PLoS Genet (2015) 0.81
Colonization potential to reconstitute a microbe community in patients detected early after fecal microbe transplant for recurrent C. difficile. BMC Microbiol (2016) 0.81
Clearance of Vancomycin-Resistant Enterococcus Concomitant With Administration of a Microbiota-Based Drug Targeted at Recurrent Clostridium difficile Infection. Open Forum Infect Dis (2016) 0.80
Adult vaccination. Hum Vaccin Immunother (2014) 0.79
Gut microbiota composition and Clostridium difficile infection in hospitalized elderly individuals: a metagenomic study. Sci Rep (2016) 0.79
Factors Influencing the Gut Microbiota, Inflammation, and Type 2 Diabetes. J Nutr (2017) 0.77
Mechanisms and consequences of intestinal dysbiosis. Cell Mol Life Sci (2017) 0.76
Gut microbiome as a clinical tool in gastrointestinal disease management: are we there yet? Nat Rev Gastroenterol Hepatol (2017) 0.75
Embracing the gut microbiota: the new frontier for inflammatory and infectious diseases. Clin Transl Immunology (2017) 0.75
Intestinal Microbiota-Derived GABA Mediates Interleukin-17 Expression during Enterotoxigenic Escherichia coli Infection. Front Immunol (2017) 0.75
Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection. Aliment Pharmacol Ther (2016) 0.75
Active and Secretory IgA-Coated Bacterial Fractions Elucidate Dysbiosis in Clostridium difficile Infection. mSphere (2016) 0.75
Protective Effect of Carvacrol against Gut Dysbiosis and Clostridium difficile Associated Disease in a Mouse Model. Front Microbiol (2017) 0.75
Bile salt hydrolase-mediated inhibitory effect of Bacteroides ovatus on growth of Clostridium difficile. J Microbiol (2017) 0.75
Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection. Open Forum Infect Dis (2017) 0.75
Identification of donor microbe species that colonize and persist long term in the recipient after fecal transplant for recurrent Clostridium difficile. NPJ Biofilms Microbiomes (2017) 0.75
Structure, function and diversity of the healthy human microbiome. Nature (2012) 30.40
Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med (2013) 20.65
A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med (2005) 16.59
The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol (2008) 16.57
Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut (2005) 10.95
Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ (2004) 9.93
The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity (2009) 8.95
Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A (2010) 8.56
Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation. Infect Immun (2009) 7.48
Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA (2005) 6.87
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature (2013) 6.77
Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med (2000) 6.24
Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis (2008) 6.21
Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology (1978) 5.91
Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev (2005) 5.69
Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A (2010) 5.02
Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis (2007) 4.77
Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet (2001) 4.59
Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol (2010) 4.52
Colonization resistance. Antimicrob Agents Chemother (1994) 4.51
Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J Clin Microbiol (2004) 4.46
Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet (1989) 4.44
Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis (2011) 4.09
Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog (2012) 3.81
Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis (1981) 3.76
Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS One (2010) 3.64
Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome (2013) 3.56
Antibiotic treatment of clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. Infect Immun (2009) 3.36
Management of Clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis (2010) 3.31
Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet (1998) 3.29
Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ (2006) 3.18
Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis (2007) 3.15
Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect Immun (2011) 2.87
Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol (2013) 2.85
Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. EMBO Rep (2012) 2.83
Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med (2013) 2.78
Clostridium difficile carriage in healthy infants in the community: a potential reservoir for pathogenic strains. Clin Infect Dis (2012) 2.68
Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol (2010) 2.61
A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol (2008) 2.57
OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother (2008) 2.47
Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun (2014) 2.39
The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection. Gut Microbes (2011) 2.37
Clostridium difficile in long-term-care facilities for the elderly. Infect Control Hosp Epidemiol (2002) 2.27
Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. J Med Microbiol (2002) 2.18
Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980-1982. J Infect Dis (1985) 2.16
Probiotic bacteria reduce salmonella typhimurium intestinal colonization by competing for iron. Cell Host Microbe (2013) 2.06
Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis (2006) 2.03
Role of the microbiota in inflammatory bowel diseases. Inflamm Bowel Dis (2011) 1.95
Metabolism of bile salts in mice influences spore germination in Clostridium difficile. PLoS One (2010) 1.87
High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes (2013) 1.85
Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J Bacteriol (2010) 1.82
Suppression of Clostridium difficile in the gastrointestinal tracts of germfree mice inoculated with a murine isolate from the family Lachnospiraceae. Infect Immun (2012) 1.79
Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J Clin Microbiol (2013) 1.79
Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology (2014) 1.77
Bacteria, colonic fermentation, and gastrointestinal health. J AOAC Int (2012) 1.72
Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol (2012) 1.70
The distribution of Clostridium difficile in the environment of South Wales. J Med Microbiol (1996) 1.64
A new strategy for the prevention of Clostridium difficile infection. J Infect Dis (2013) 1.62
Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridum difficile-associated disease. J Infect Dis (2010) 1.62
Recovery of the gut microbiome following fecal microbiota transplantation. MBio (2014) 1.59
Characterization of the sporulation initiation pathway of Clostridium difficile and its role in toxin production. J Bacteriol (2009) 1.57
Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol (2002) 1.53
Chenodeoxycholate is an inhibitor of Clostridium difficile spore germination. J Bacteriol (2008) 1.53
Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol (2013) 1.52
Clostridium difficile infection in infants and children. Pediatrics (2012) 1.48
Lack of association of tcdC type and binary toxin status with disease severity and outcome in toxigenic Clostridium difficile. J Infect (2011) 1.45
Clostridium difficile binary toxin CDT: mechanism, epidemiology, and potential clinical importance. Gut Microbes (2013) 1.41
Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol (2008) 1.40
Microbiome data distinguish patients with Clostridium difficile infection and non-C. difficile-associated diarrhea from healthy controls. MBio (2014) 1.40
Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J Clin Microbiol (2011) 1.34
Spores of Clostridium difficile clinical isolates display a diverse germination response to bile salts. PLoS One (2012) 1.31
Diminished Clostridium difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor. J Clin Invest (1992) 1.28
Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection. PLoS One (2013) 1.24
Clostridium difficile infection: the scope of the problem. J Hosp Med (2012) 1.24
Clostridium difficile colonization in early infancy is accompanied by changes in intestinal microbiota composition. J Clin Microbiol (2010) 1.21
Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent Clostridium difficile infection. ISME J (2014) 1.19
Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production. Antimicrob Agents Chemother (2010) 1.16
The effect of proton pump inhibitors on the human microbiota. Curr Drug Metab (2009) 1.16
Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection. Antimicrob Agents Chemother (2014) 1.14
Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agents Chemother (2012) 1.13
Clostridium difficile infection in the inflammatory bowel disease patient. Inflamm Bowel Dis (2013) 1.09
Clostridium difficile infection in the elderly. Clin Geriatr Med (2014) 1.05
Gut microbiota patterns associated with colonization of different Clostridium difficile ribotypes. PLoS One (2013) 0.98
Colonic IgA producing cells and macrophages are reduced in recurrent and non-recurrent Clostridium difficile associated diarrhoea. J Clin Pathol (2004) 0.95
Antimicrobial use and risk for recurrent Clostridium difficile infection. Am J Med (2011) 0.94
Tigecycline for the treatment of severe Clostridium difficile infection. Ann Pharmacother (2011) 0.93
Heterogeneity of Clostridium difficile isolates from infants. Eur J Pediatr (1993) 0.93
Fidaxomicin "chaser" regimen following vancomycin for patients with multiple Clostridium difficile recurrences. Clin Infect Dis (2012) 0.92
Nontoxigenic Clostridium difficile protects hamsters against challenge with historic and epidemic strains of toxigenic BI/NAP1/027 C. difficile. Antimicrob Agents Chemother (2013) 0.91
Stratification and compartmentalisation of immunoglobulin responses to commensal intestinal microbes. Semin Immunol (2013) 0.90
Immunoglobulin and non-immunoglobulin components of human milk inhibit Clostridium difficile toxin A-receptor binding. J Med Microbiol (1995) 0.86
The impact of intestinal inflammation on the nutritional environment of the gut microbiota. Immunol Lett (2014) 0.83
Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection. Antimicrob Agents Chemother (2009) 0.82
Effect of proton pump inhibitor pantoprazole on growth and morphology of oral Lactobacillus strains. Laryngoscope (2008) 0.80
Single nucleotide polymorphisms of the tcdC gene and presence of the binary toxin gene predict recurrent episodes of Clostridium difficile infection. Ann Surg (2014) 0.78
Diverse sources of C. difficile infection. N Engl J Med (2014) 0.77
Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation. Infect Immun (2009) 7.48
Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis (2008) 6.21
Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One (2011) 4.65
Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis (2012) 4.34
Comparison of the respiratory microbiome in healthy nonsmokers and smokers. Am J Respir Crit Care Med (2013) 3.65
Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci U S A (2012) 3.43
From structure to function: the ecology of host-associated microbial communities. Microbiol Mol Biol Rev (2010) 2.42
The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection. Gut Microbes (2011) 2.37
Changes in cystic fibrosis airway microbiota at pulmonary exacerbation. Ann Am Thorac Soc (2013) 2.05
Evolutionary genetics of a new pathogenic Escherichia species: Escherichia albertii and related Shigella boydii strains. J Bacteriol (2005) 2.01
Significance of the microbiome in obstructive lung disease. Thorax (2012) 1.97
Alteration of the murine gut microbiota during infection with the parasitic helminth Heligmosomoides polygyrus. Inflamm Bowel Dis (2010) 1.85
Suppression of Clostridium difficile in the gastrointestinal tracts of germfree mice inoculated with a murine isolate from the family Lachnospiraceae. Infect Immun (2012) 1.79
Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol (2012) 1.70
Colonization of the cecal mucosa by Helicobacter hepaticus impacts the diversity of the indigenous microbiota. Infect Immun (2005) 1.67
Widespread colonization of the lung by Tropheryma whipplei in HIV infection. Am J Respir Crit Care Med (2013) 1.66
Relationship between COMLEX and USMLE scores among osteopathic medical students who take both examinations. Teach Learn Med (2010) 1.60
The microbiome of the lung. Transl Res (2012) 1.59
Perturbation of the small intestine microbial ecology by streptomycin alters pathology in a Salmonella enterica serovar typhimurium murine model of infection. Infect Immun (2009) 1.59
Antibiotic administration alters the community structure of the gastrointestinal micobiota. Gut Microbes (2010) 1.57
Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals. MBio (2015) 1.56
Depression, antidepressant medications, and risk of Clostridium difficile infection. BMC Med (2013) 1.54
Stabilization of the murine gut microbiome following weaning. Gut Microbes (2012) 1.49
Microbial ecology of the murine gut associated with the development of dextran sodium sulfate-induced colitis. Inflamm Bowel Dis (2010) 1.44
Impact of enhanced Staphylococcus DNA extraction on microbial community measures in cystic fibrosis sputum. PLoS One (2012) 1.40
Microbiome data distinguish patients with Clostridium difficile infection and non-C. difficile-associated diarrhea from healthy controls. MBio (2014) 1.40
Candida albicans and bacterial microbiota interactions in the cecum during recolonization following broad-spectrum antibiotic therapy. Infect Immun (2012) 1.36
The gut microbiome in health and in disease. Curr Opin Gastroenterol (2015) 1.33
Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains. Gut Microbes (2011) 1.29
Application of a neutral community model to assess structuring of the human lung microbiome. MBio (2015) 1.25
Streptococcus intermedius causing infective endocarditis and abscesses: a report of three cases and review of the literature. BMC Infect Dis (2008) 1.23
Procalcitonin levels associate with severity of Clostridium difficile infection. PLoS One (2013) 1.22
Variation of the natural transformation frequency of Campylobacter jejuni in liquid shake culture. Microbiology (2003) 1.21
Pathogenesis of renal disease due to enterohemorrhagic Escherichia coli in germ-free mice. Infect Immun (2008) 1.20
A gene-targeted approach to investigate the intestinal butyrate-producing bacterial community. Microbiome (2013) 1.17
Modulation of host immune responses by the cytolethal distending toxin of Helicobacter hepaticus. Infect Immun (2006) 1.16
Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection. Antimicrob Agents Chemother (2014) 1.14
The relationship between phenotype, ribotype, and clinical disease in human Clostridium difficile isolates. Anaerobe (2013) 1.14
Understanding increased mortality in Clostridium difficile-infected older adults. Clin Infect Dis (2013) 1.13
Disruption of the human gut microbiota following Norovirus infection. PLoS One (2012) 1.13
Ecological succession of bacterial communities during conventionalization of germ-free mice. Appl Environ Microbiol (2012) 1.09
Explaining unexplained diarrhea and associating risks and infections. Anim Health Res Rev (2007) 1.08
Interplay between the gastric bacterial microbiota and Candida albicans during postantibiotic recolonization and gastritis. Infect Immun (2011) 1.07
Poor functional status as a risk factor for severe Clostridium difficile infection in hospitalized older adults. J Am Geriatr Soc (2013) 1.05
Laser capture microdissection and metagenomic analysis of intact mucosa-associated microbial communities of human colon. Appl Microbiol Biotechnol (2010) 1.05
Clostridium difficile ribotype diversity at six health care institutions in the United States. J Clin Microbiol (2013) 1.04
Effect of sample storage conditions on culture-independent bacterial community measures in cystic fibrosis sputum specimens. J Clin Microbiol (2011) 1.03
Comparison of brush and biopsy sampling methods of the ileal pouch for assessment of mucosa-associated microbiota of human subjects. Microbiome (2014) 1.00
Genetic diversity of Campylobacter sp. isolates from retail chicken products and humans with gastroenteritis in Central Michigan. J Clin Microbiol (2005) 0.99
Stress-induced corticotropin-releasing hormone-mediated NLRP6 inflammasome inhibition and transmissible enteritis in mice. Gastroenterology (2013) 0.98
Challenges in IBD research: update on progress and prioritization of the CCFA's research agenda. Inflamm Bowel Dis (2013) 0.97
Lethal toxin is a critical determinant of rapid mortality in rodent models of Clostridium sordellii endometritis. Anaerobe (2009) 0.95
Non-toxigenic Clostridium sordellii: clinical and microbiological features of a case of cholangitis-associated bacteremia. Anaerobe (2011) 0.93
Interactions Between the Gastrointestinal Microbiome and Clostridium difficile. Annu Rev Microbiol (2015) 0.93
Acute infection of mice with Clostridium difficile leads to eIF2α phosphorylation and pro-survival signalling as part of the mucosal inflammatory response. Immunology (2013) 0.93
Inflammatory bowel disease causes reversible suppression of osteoblast and chondrocyte function in mice. Am J Physiol Gastrointest Liver Physiol (2009) 0.92
A clinical and epidemiological review of non-toxigenic Clostridium difficile. Anaerobe (2013) 0.91
Faecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection: current promise and future needs. Curr Opin Gastroenterol (2013) 0.89
Emerging Insights into Antibiotic-Associated Diarrhea and Clostridium difficile Infection through the Lens of Microbial Ecology. Interdiscip Perspect Infect Dis (2008) 0.89
Impact of oral typhoid vaccination on the human gut microbiota and correlations with s. Typhi-specific immunological responses. PLoS One (2013) 0.89
Murine models to study Clostridium difficile infection and transmission. Anaerobe (2013) 0.89
Colitis-induced bone loss is gender dependent and associated with increased inflammation. Inflamm Bowel Dis (2013) 0.84
Leptin acts independently of food intake to modulate gut microbial composition in male mice. Endocrinology (2014) 0.82
Interleukin-22 and CD160 play additive roles in the host mucosal response to Clostridium difficile infection in mice. Immunology (2015) 0.81
Murine norovirus infection does not cause major disruptions in the murine intestinal microbiota. Microbiome (2013) 0.80
The role of Gr-1(+) cells and tumour necrosis factor-α signalling during Clostridium difficile colitis in mice. Immunology (2015) 0.80
A randomised trial of sheathed versus standard forceps for obtaining uncontaminated biopsy specimens of microbiota from the terminal ileum. Gut (2011) 0.79
Fecal microbiota therapy: ready for prime time? Infect Control Hosp Epidemiol (2013) 0.79
Corrigendum: Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat Immunol (2016) 0.77
Serum 25-Hydroxyvitamin D Levels are not Associated with Adverse Outcomes in Clostridium Difficile Infection. Infect Dis Rep (2015) 0.76
Spherules, hyphae, and air-crescent sign. Am J Med Sci (2008) 0.75
Reply to Walker et al. Clin Infect Dis (2013) 0.75
Reply to McDonald. Clin Infect Dis (2012) 0.75
Corrigendum: NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growth. Nat Immunol (2017) 0.75
Erratum: NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growth. Nat Immunol (2017) 0.75